AR085484A1 - ANTICUERPOS QUE SE UNEN A TGF-a Y EPIREGULINA - Google Patents

ANTICUERPOS QUE SE UNEN A TGF-a Y EPIREGULINA

Info

Publication number
AR085484A1
AR085484A1 ARP120100945A ARP120100945A AR085484A1 AR 085484 A1 AR085484 A1 AR 085484A1 AR P120100945 A ARP120100945 A AR P120100945A AR P120100945 A ARP120100945 A AR P120100945A AR 085484 A1 AR085484 A1 AR 085484A1
Authority
AR
Argentina
Prior art keywords
seq
epiregulin
antibodies
tgf
heavy chain
Prior art date
Application number
ARP120100945A
Other languages
English (en)
Spanish (es)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR085484A1 publication Critical patent/AR085484A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP120100945A 2011-04-06 2012-03-22 ANTICUERPOS QUE SE UNEN A TGF-a Y EPIREGULINA AR085484A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161472338P 2011-04-06 2011-04-06

Publications (1)

Publication Number Publication Date
AR085484A1 true AR085484A1 (es) 2013-10-02

Family

ID=45929050

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP120100945A AR085484A1 (es) 2011-04-06 2012-03-22 ANTICUERPOS QUE SE UNEN A TGF-a Y EPIREGULINA
ARP210102953A AR123912A2 (es) 2011-04-06 2021-10-25 ANTICUERPOS QUE SE UNEN A TGF-a Y EPIREGULINA

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP210102953A AR123912A2 (es) 2011-04-06 2021-10-25 ANTICUERPOS QUE SE UNEN A TGF-a Y EPIREGULINA

Country Status (26)

Country Link
US (1) US8613921B2 (enExample)
EP (1) EP2694547B1 (enExample)
JP (1) JP2014515743A (enExample)
KR (1) KR101581517B1 (enExample)
CN (1) CN103459423B (enExample)
AR (2) AR085484A1 (enExample)
AU (1) AU2012240508B2 (enExample)
BR (1) BR112013023513A2 (enExample)
CA (1) CA2832256C (enExample)
CY (1) CY1116332T1 (enExample)
DK (1) DK2694547T3 (enExample)
EA (1) EA024921B1 (enExample)
ES (1) ES2539503T3 (enExample)
HR (1) HRP20150468T1 (enExample)
IL (1) IL228101A0 (enExample)
ME (1) ME02063B (enExample)
MX (1) MX2013011596A (enExample)
PL (1) PL2694547T3 (enExample)
PT (1) PT2694547E (enExample)
RS (1) RS54000B1 (enExample)
SG (1) SG193452A1 (enExample)
SI (1) SI2694547T1 (enExample)
TW (1) TWI454481B (enExample)
UA (1) UA110051C2 (enExample)
WO (1) WO2012138510A1 (enExample)
ZA (1) ZA201306813B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4045641A1 (en) 2019-10-15 2022-08-24 Eli Lilly and Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
TWI807338B (zh) * 2020-06-26 2023-07-01 美商美國禮來大藥廠 結合ＴＧＦ-α及表皮調節素（ＥＰＩＲＥＧＵＬＩＮ）之抗體於治療疼痛之用途
KR102495473B1 (ko) * 2020-10-06 2023-02-06 서울대학교병원 앰피레귤린을 유효성분으로 포함하는 안질환 치료용 조성물
TWI859538B (zh) 2021-05-21 2024-10-21 美商美國禮來大藥廠 靶向表皮調節素(epiregulin)之化合物及方法
CN119213026A (zh) * 2022-03-04 2024-12-27 耶鲁大学 用于治疗和预防纤维化的方法和组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190858A (en) 1989-02-01 1993-03-02 Oncogene Science, Inc. Monoclonal antibodies directed to epitopes of human transforming growth factor--α and uses thereof
JP5919593B2 (ja) 2006-10-11 2016-05-18 フージョン アンティボディーズ リミテッド 併用療法
RU2537245C2 (ru) 2006-10-12 2014-12-27 Чугаи Сейяку Кабусики Кайся Диагностика и лечение злокачественной опухоли с использованием антитела против ereg
GB0807018D0 (en) * 2008-04-17 2008-05-21 Fusion Antibodies Ltd Antibodies and treatment
EP2436397B1 (en) * 2009-05-29 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition containing antagonist of egf family ligand as component

Also Published As

Publication number Publication date
US20120258109A1 (en) 2012-10-11
CA2832256C (en) 2016-02-09
DK2694547T3 (en) 2015-04-27
EA201370196A1 (ru) 2014-02-28
UA110051C2 (uk) 2015-11-10
RS54000B1 (sr) 2015-10-30
IL228101A0 (en) 2013-09-30
PL2694547T3 (pl) 2015-08-31
JP2014515743A (ja) 2014-07-03
MX2013011596A (es) 2013-12-09
KR101581517B1 (ko) 2015-12-30
PT2694547E (pt) 2015-06-01
EP2694547A1 (en) 2014-02-12
TW201300414A (zh) 2013-01-01
KR20130133274A (ko) 2013-12-06
AU2012240508B2 (en) 2014-10-23
SG193452A1 (en) 2013-10-30
CY1116332T1 (el) 2017-02-08
HRP20150468T1 (hr) 2015-06-05
AU2012240508A1 (en) 2013-08-29
WO2012138510A1 (en) 2012-10-11
ZA201306813B (en) 2015-04-29
SI2694547T1 (sl) 2015-05-29
CN103459423A (zh) 2013-12-18
NZ614198A (en) 2015-09-25
ME02063B (me) 2015-05-20
AR123912A2 (es) 2023-01-25
ES2539503T3 (es) 2015-07-01
EA024921B1 (ru) 2016-11-30
US8613921B2 (en) 2013-12-24
TWI454481B (zh) 2014-10-01
BR112013023513A2 (pt) 2016-11-22
CA2832256A1 (en) 2012-10-11
HK1190410A1 (en) 2014-07-04
CN103459423B (zh) 2016-03-02
EP2694547B1 (en) 2015-03-18

Similar Documents

Publication Publication Date Title
PE20210045A1 (es) Anticuerpos agonistas contra pd-1 y usos de estos
PE20200294A1 (es) Anticuerpos que se unen especificamente a pd-1 y metodos de uso
PE20141147A1 (es) Anticuerpos a pcsk9 y usos de los mismos
NZ603607A (en) Cgrp antibodies
PE20180604A1 (es) Anticuerpos pd-l1 (que se unen al ligando 1 de muerte celular programada 1 humana)
PE20181921A1 (es) NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS
AR103713A1 (es) Anticuerpos contra tau y sus usos
NZ610294A (en) Human antibodies to human tnf-like ligand 1a (tl1a)
CO6230999A2 (es) Anticuerpo anti-esclerostina
AR123912A2 (es) ANTICUERPOS QUE SE UNEN A TGF-a Y EPIREGULINA
PE20212088A1 (es) Anticuerpos anti-tau y uso de los mismos
PE20130226A1 (es) Anticuerpos hacia gdf8 humano
PE20210132A1 (es) Anticuerpos anti-cd3 y usos de estos
PE20200011A1 (es) ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS
PE20190630A1 (es) Anticuerpos de anti-tim-3
PE20141151A1 (es) Proteinas de union al antigeno cd27l
PE20181326A1 (es) Anticuerpos que se unen especificamente a pd-1 y sus usos
NZ628943A (en) Human antibodies to clostridium difficile toxins
PE20130817A1 (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos
AR110203A1 (es) Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1
MX389805B (es) Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38.
AR098663A1 (es) Anticuerpos multifuncionales que se unen a egfr y met
PE20091351A1 (es) Anticuerpos humanizados especificos para el factor von willebrand
PE20150159A1 (es) Composiciones y metodos para anticuerpos que actuan sobre el factor p
EA035160B9 (ru) Антитела к st2 и их применение

Legal Events

Date Code Title Description
FG Grant, registration